The date format must match "dd.mm.YYYY"
In two early benefit assessments, IQWiG was unable to derive an added benefit from the data presented because current standards of care were not implemented in the studies.
NIPD can reduce the number of invasive tests and hence the number of test-related miscarriages in women whose foetuses are at an increased risk of trisomy 21.
IQWiG researchers involved in the early benefit assessment of palbociclib wrote a letter to the editor on the analysis of data from the PALOMA-2 study.
IQWiG published its updated methods in 2017, including new chapters on HTA topics proposed by the public and on the assessment of high-risk medical devices. An English translation is now available.
An update of the 2013 assessment shows that, due to a lack of suitable studies, data are missing for people with a family history of colorectal cancer.
The new non-invasive test, using a blood sample of the pregnant woman, is as reliable as the conventional test using a blood sample of the newborn. Studies on benefit and harm are still lacking.
The search update for a possible disease management programme “osteoporosis” showed that integrated concepts of medical and physical rehabilitation were hardly addressed.
An indication or hint of greater benefit was now shown for six instead of two therapeutic measures. This applies particularly to the attachment level.
If only 2 to 4 studies are available, meta-analyses often do not lead to informative results. However, suitable methods for evidence syntheses are available, even in the event of sparse evidence.
Regular use of fluoride varnish can prevent caries in primary teeth. Advantages or disadvantages regarding further patient-relevant outcomes remain unclear due to a lack of data.
Almost all health care aspects need to be updated. The already third search update for guidelines shows that their number and quality have increased notably in 10 years.
The first neurodermatitis drug undergoing the AMNOG procedure provides better symptom relief and has clear advantages particularly in the quality of life.
The data showed no relevant differences for some outcome criteria, and data were missing for others – also because some studies remain incompletely published.
A host of dossiers assessed by IQWiG to date have addressed oncology drugs. Despite their significance, other diseases, e.g. Alzheimer dementia, are underrepresented.
IQWiG authors report on the availability of randomized controlled trials (RCTs) of newly approved drugs in trial registries as well as on specific search strategies.
Four dossier assessments in 2017 involving comparisons between immunotherapies and chemotherapies for the same indication. Yet, a comparison of immunotherapies among each other is missing.
In their updated guideline, US oncologists recently recommended the MammaPrint test. Researchers from IQWiG have reacted in a letter to the editor in the Journal of Clinical Oncology.
There is an indication of considerable added benefit in progression up to six months after platinum-based therapy. An added benefit is not proven for progression occurring later.
No added benefit can be derived from the incompletely submitted data for adolescents or adults. The postulated better tolerability is not proven.
There were notably more remissions than under the comparator therapies. In future, the analysis of symptoms should not be limited to improvements at one time point.
Dr. Anna-Sabine Ernst
+49 221 35685-153
+49 221 35685-158
To save your search result, please copy the link below and paste it into a new tab/window.